Trastuzumab deruxtecan: beside a new treatment under test
33 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdNot yet recruitingNCT07836257Phase 2How we knowReport a problem
- Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast CancerNot yet recruitingNCT07785856Phase 1/2How we knowReport a problem
- A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerRecruitingNCT07701941Phase 1/2How we knowReport a problem
- Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer StudyRecruitingNCT07647016Phase 2How we knowReport a problem
- Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast CancersRecruitingNCT07553390Phase 1How we knowReport a problem
- ctDNA-guided Treatment Decision-makingRecruitingNCT07394218Phase 2How we knowReport a problem
- A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerRecruitingNCT07294508Phase 2/3How we knowReport a problem
- CVL006 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07157956Phase 1/2How we knowReport a problem
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerRecruitingNCT07137416Phase 1How we knowReport a problem
- Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT07086768Phase 1How we knowReport a problem
- A Study of PHST001 in Advanced Solid TumorsRecruitingNCT06840886Phase 1How we knowReport a problem
- A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer PatientsRecruitingNCT06832202Phase 2How we knowReport a problem
- EIS-12656 as Single Agent and in Combination in Patients With Specified Solid TumorsRecruitingNCT06525298Phase 1/2How we knowReport a problem
- Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsRecruitingNCT06364410Phase 1How we knowReport a problem
- Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast CancerRecruitingNCT06331169Phase 1How we knowReport a problem
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Phase 1/2How we knowReport a problem
- Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer TrialNot yet recruitingNCT06245824Phase 4How we knowReport a problem
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingNCT05868226Phase 1/2How we knowReport a problem
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)RecruitingNCT05824975Phase 1/2How we knowReport a problem
- A Study of DB-1310 in Advanced/Metastatic Solid TumorsRecruitingNCT05785741Phase 1/2How we knowReport a problem
- A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT05765851Phase 1How we knowReport a problem
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingNCT05614739Phase 1How we knowReport a problem
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT05417594Phase 1/2How we knowReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2How we knowReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2How we knowReport a problem
- A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersTerminatedNCT05091528Phase 1/2Results postedHow we knowReport a problem
- A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedNCT04916002Phase 2Results postedHow we knowReport a problem
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruitingNCT06771622Phase 1/2How we knowReport a problem
- A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid TumorsActive, not recruitingNCT06244485Phase 1How we knowReport a problem
- ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerActive, not recruitingNCT05650879Phase 1How we knowReport a problem
- Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast CancerActive, not recruitingNCT05633979Phase 1How we knowReport a problem
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1How we knowReport a problem
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2How we knowReport a problem